BREAST CANCER NOW: Determining the role of the epigenetic reader bromodomain protein 3 in invasive lobular carcinoma. Invasive lobular carcinoma (ILC) is the second most common type of breast cancer accounting for approximately 10% of all breast tumours. ILC is characterised by a loss of E-cadherin and it is generally oestrogen receptor positive. We aim to decipher the exact role of each Brd protein in ILC using RNA-seq and CHIP-seq.
AbbVie Funded research project: Determining anti-apoptotic dependencies in Multiple Myeloma.
Using BH3 profiling we aim to determine if we can switch anti-apoptotic dependencies in Multiple Myeloma.
StAR RCSI Award: Assessing the role of the microenvironment on T-cell acute lympoblastic leukemia anti-apoptotic dependence. We utilize state-of-the-art technology BH3 profiling to determine sensitivity to apoptosis and anti-apoptotic dependencies for discovering targeted therapeutics in T-cell acute lymphoblastic leukaemia.
H2020: PI on Marie Skłodowska-Curie Action Global Fellowship “Development of a novel genetically engineered mouse model to study the role of HDAC6 in oncogenesis and metastasis of non-small cell lung cancer.”
In Europe lung cancer is the second most common cancer in men and the third most common cancer in women. Approximately 70% of all newly diagnosed patients present with local advanced or metastatic disease, requiring systemic chemotherapy. NSCLC accounts for nearly 85% of all cases of lung cancer. Despite the discovery of novel targeted therapies there is still a poor prognosis for lung cancer due to drug resistance and tumor recurrence. The aim of this project is to determine the role of HDAC6 in NSCLC tumour initiation and metastasis using genetically engineered mouse models.
Click here for more information on the projects